<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597739</url>
  </required_header>
  <id_info>
    <org_study_id>CR100801</org_study_id>
    <secondary_id>40346527ARA2001</secondary_id>
    <secondary_id>2011-004529-28</secondary_id>
    <nct_id>NCT01597739</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy</brief_title>
  <official_title>A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of
      JNJ-40346527 200 mg/day (100 mg twice daily) for 12 weeks, compared with placebo, in patients
      with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD)
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (treatment assigned by chance, like flipping a coin), multicenter,
      double-blind (neither physician nor patient will know the treatment the patient receives),
      parallel-group (each group of patients will be treated at the same time) study. JNJ-40346527
      will be compared to a placebo, which is an inactive substance used to test whether a drug has
      a real effect. Patients will receive study medication for 12 weeks and will continue their
      permitted, stable DMARD therapy (methotrexate [MTX], sulfasalazine [SSZ], and/or
      hydroxychloroquine [HCQ]) through Week 12. A follow-up visit will occur 4 weeks after dosing
      is complete. The maximum length of patient participation will be 22 weeks, including a 6-week
      screening period. Other study visits will occur during the study, and patient safety will be
      monitored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Disease Activity Score (DAS28), using C-reactive protein (CRP)</measure>
    <time_frame>Week 12</time_frame>
    <description>The DAS28 is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP, and an overall assessment of disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR 20 response</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR 20 (American College of Rheumatology) response is a 20% improvement in rheumatoid arthritis (RA) symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 (using CRP) response</measure>
    <time_frame>Week 12</time_frame>
    <description>DAS28 response is the improvement from baseline and is rated as &quot;No response,&quot; Moderate response,&quot; or &quot;Good response.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>JNJ-40346527</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-40346527</intervention_name>
    <description>Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.</description>
    <arm_group_label>JNJ-40346527</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Form=capsule; route=oral use; twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) for at least 6 months prior to screening

          -  Have been positive for, or are positive at screening for, either anti-cyclic
             citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum

          -  Have active RA with at least 6 swollen and 6 tender joints, using a 66/68 joint count
             at the time of screening and at baseline, and serum C-reactive protein (CRP) &gt;= 0.80
             mg/dL at screening

          -  Have been treated with and tolerated at least one of the following medications for a
             minimum of 6 months prior to screening and must be on a stable dose for a minimum of 8
             weeks prior to screening: methotrexate (MTX) treatment at dosages of 7.5 to 25
             mg/week, inclusive; sulfasalazine not exceeding 3 g/d; hydroxychloroquine not
             exceeding 400 mg/d

          -  If using nonsteroidal antiinflammatory drugs (NSAIDs), or other analgesics regularly
             for RA, patients must have been on a stable dose for at least 2 weeks prior to the
             first administration of study agent. If not using NSAIDs or other analgesics for RA,
             the patient must have not received NSAIDs or other analgesics for at least 2 weeks
             prior to the first administration of study agent

          -  If using oral corticosteroids, must be on a stable dose of &lt;= 10 mg/day of prednisone
             or an equipotent dose of another oral corticosteroid for at least 2 weeks prior to the
             first administration of study agent. If not using corticosteroids, the patient must
             have not received oral corticosteroids for at least 2 weeks prior to the first
             administration of study agent

        Exclusion Criteria:

          -  Has inflammatory diseases other than RA, including but not limited to adult onset
             Still's disease, psoriatic arthritis, ankylosing spondylitis, systemic lupus
             erythematosus, and Lyme disease that might confound the evaluation of the benefit of
             study agent therapy

          -  Has a history of juvenile idiopathic arthritis (JIA)

          -  Has current signs or symptoms of liver or renal insufficiency or cardiac, vascular,
             pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or
             metabolic disturbances that are severe, progressive, or uncontrolled

          -  Has been treated in the time frames specified with any nonbiologic disease-modifying
             antirheumatic drugs (DMARDs), except for MTX, sulfasazine, and hydroxychloroquine,
             including, but not limited to: D-penicillamine, oral or parenteral gold salts,
             azathioprine, cyclosporine, tacrolimus, and mycophenolate mofetil within 4 weeks prior
             to the first administration of study agent; leflunomide within 12 weeks prior to the
             first administration of study agent unless the subject has undergone a drug
             elimination procedure at least 4 weeks prior to the first administration of study
             agent; any investigational nonbiologic DMARD within 4 weeks prior to the first
             administration of study agent or 5 half-lives of the DMARD, whichever is longer

          -  Has ever received any approved or investigational biologic antirheumatic agent. These
             agents include, but are not limited to, infliximab, golimumab, certolizumab pegol,
             etanercept, adalimumab, abatacept, rituximab, tocilizumab, or anakinra.

          -  Has received drugs that potently inhibit or induce cytochrome P450 (CYP450) 3A4,
             CYP2C8, or CYP2C19 isoforms within 2 weeks or within 5 half-lives of the drug,
             whichever is longer, prior to the first dose of study medication

          -  Has received intra-articular, epidural, intravertebral, intramuscular, or intravenous
             corticosteroids, including adrenocorticotropic hormone, within 4 weeks prior to the
             first dose of study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel De Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevlievo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veliko Turnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatvan</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sziksz√≥</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulyanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=3469&amp;filename=CR100801_CSR.pdf</url>
    <description>A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of JNJ-40346527 in Subjects With Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy</keyword>
  <keyword>Disease-modifying antirheumatic drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

